Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target.
All initial product development activities such as cell line development, formulation, manufacturing and clinical trials will be coordinated by Innovent, while the development, manufacturing and commercialisation of the therapeutic antibody will be jointly coordinated by both the parties.
Adimab chief executive officer Tillman Gerngross said, “They have built a remarkable manufacturing infrastructure and we are confident in their ability to develop attractive programs for the Chinese market.”
While Innovent will be reimbursed for specific development costs, Adimab will be compensated for the discovery and optimisation of the therapeutic leads.
Innovent retains rights to develop and commercialise the therapeutic programme in China, with sales-based royalties owed to Adimab, which will retain rights for commercialization in the US, Europe and Japan with product sales-based royalties owed to Innovent.
Commenting on the partnership, Innovent chief executive officer Michael Yu said, “We feel that combining the Adimab platform with Innovent’s strong development and manufacturing capabilities will help us to rapidly build a strong therapeutic pipeline and commercial presence in China.”
Additionally, Adimab has announced the achievement of technical milestones from its ongoing collaborations with Eli Lilly and Company, Gilead, and Kyowa Hakko Kirin.
